HR — what changed in the latest 10-Q
A section-by-section comparison of HR's newest periodic SEC filing (10-K/10-Q) against the prior same-form filing: paragraphs added and removed per section, with verbatim excerpts. Purely a deterministic text diff — no similarity scores, no directional read, not investment advice.
Comparing 10-Q · 2026-10-29 vs the prior 10-Q · 2026-07-30
| Section | Outcome | Added | Removed | Minor | Unchanged |
|---|---|---|---|---|---|
| MD&A | Text added/removed | +62 | −51 | ~46 | 73 |
| Market risk (Item 3) | Text added/removed | 0 | 0 | ~1 | 0 |
| Controls & procedures | No paragraph-level changes | 0 | 0 | 0 | 2 |
| Legal proceedings | No paragraph-level changes | 0 | 0 | 0 | 1 |
| Risk factors | No material changes reported (points to the 10-K) | — | — | — | — |
| Other information | Text added/removed | 0 | 0 | ~1 | 0 |
Counts are paragraphs; added/removed means text added or removed vs the prior filing — no direction or judgement implied.
Representative excerpts
Up to 5 excerpts of about 300 characters per section, quoted verbatim from the two SEC filings.
MD&A
Text added vs the prior filing · source: 10-Q · 2026-10-29
Cash flows used in investing activities for the nine months ended September 30, 2026 were approximately $113.7 million and cash flows provided by investing activities for the nine months ended September 30, 2025 were $184.3 million. Below is a summary of the investing activities.
On October 22, 2026, the Company sold one medical office building, comprising 59,427 square feet, and a garage in Atlanta, GA for a total purchase price of $36.0 million.
On October 22, 2026, an unconsolidated joint venture where the Company owns 20% acquired two properties for a total purchase price of $51.7 million, for which the Company contributed $10.3 million.
In April 2026, the Company entered into a mezzanine loan agreement to provide funding up to $6.3 million for a future development. As of September 30, 2026, $3.4 million of funding has been provided.
In April 2026, the Company received $45.2 million upon maturity of a mortgage loan. In September 2026, the Company received $6.7 million upon the payoff of a mortgage loan.
Text removed vs the prior filing · source: 10-Q · 2026-07-30
Cash flows used in investing activities for the six months ended June 30, 2026 and June 30, 2025, were approximately $52.3 million and $41.9 million, respectively. Below is a summary of the investing activities.
On July 2, 2026, the Company sold two land parcels in Dallas, TX for a total purchase price of $5.5 million.
In April 2026, the Company entered into a mezzanine loan agreement to provide funding up to $6.3 million for a future development. As of June 30, 2026, no funding has been provided.
In April 2026, the Company received $45.2 million, upon maturity of a mortgage loan.
In addition to FFO, the Company presents Normalized FFO and FAD. Normalized FFO is presented by adding acquisition-related costs, acceleration of debt issuance costs, debt extinguishment costs, restructuring, severance and other Company-defined normalizing items to evaluate operating performance. FA…
How to read Risk Factors (Item 1A) in a 10-Q
A 10-Q risk-factor section usually takes one of three forms; this page classifies it as one of:
- Pointer — the filer states there have been no material changes and points back to the annual 10-K risk factors; there is no own risk text to compare this quarter.
- Partial update — the filer carves out specific updated risks ("except as set forth below"); the excerpts show exactly what is new this quarter.
- Restated in full — the quarter carries the complete risk-factor text. When the prior quarter was only a pointer there is no prior full text to diff against, so the page flags the section as restated instead.
This describes the filing structure only — it is never a judgement on whether risk went up or down.
Source: text-level diff of the two SEC EDGAR filings · deterministic (no AI-generated content) · for reference only · not investment advice